ABIVAX Société Anonyme (ETR:2X1)

Market Cap	9.20B +2,663.1%
Revenue (ttm)	4.92M -59.8%
Net Income	-332.20M
EPS	-4.52
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50
Open	105.10
Previous Close	85.40
Day's Range	105.10 - 105.10
52-Week Range	60.85 - 132.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 21, 2026

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 80
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 2X1

Financial Performance

In 2025, ABIVAX Société Anonyme's revenue was 4.57 million, a decrease of -63.22% compared to the previous year's 12.43 million. Losses were -336.10 million, 90.7% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 30, 2026

Data Sources Report a data error